Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03132129
Other study ID # 0580
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date October 24, 2017
Est. completion date October 31, 2029

Study information

Verified date January 2024
Source University of Leicester
Contact Gerry P McCann, MD
Phone 01162583402
Email gpm12@le.ac.uk
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Background: Heart failure is a major cause of morbidity and mortality in diabetes mellitus, but its pathophysiology is poorly understood. Aim: To determine the prevalence and determinants of subclinical cardiovascular dysfunction in adults with type 2 diabetes (T2D). Plan: 518 asymptomatic adults (aged 18-75 years) with T2D will undergo comprehensive evaluation of cardiac structure and function using cardiac MRI (CMR) and spectroscopy, echocardiography, CT coronary calcium scoring, exercise tolerance testing and blood sampling. 75 controls will undergo the same evaluation. Primary hypothesis: myocardial steatosis is an independent predictor of left ventricular global longitudinal strain. Secondary hypotheses: will assess whether CMR is more sensitive to detect early cardiac dysfunction than echocardiography and BNP, and whether cardiac dysfunction is related to peak oxygen consumption. Expected value of results: This study will reveal the prevalence and determinants of cardiac dysfunction in T2D, and could provide targets for novel therapies.


Recruitment information / eligibility

Status Recruiting
Enrollment 593
Est. completion date October 31, 2029
Est. primary completion date October 31, 2029
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 50 Years to 75 Years
Eligibility Inclusion Criteria: - Participant is willing and able to give informed consent for participation in the study. - Male or Female, aged =18 and =75 years. - Diagnosed with Stable type 2 diabetes (determined by: i) formal diagnosis in GP case records, ii) a record of diagnostic oral glucose tolerance test OR glycated haemoglobin level =6.5%). Exclusion Criteria: - Angina pectoris or limiting dyspnoea (>NYHA II), - Major atherosclerotic disease: Symptomatic CAD, history of myocardial infarction, previous revascularisation, stroke/transient ischaemic attack or symptomatic peripheral vascular disease. - Atrial fibrillation or flutter. - Moderate or severe valvular heart disease. - History of heart failure or cardiomyopathy. - Type 1 diabetes mellitus (T1DM). - Low fasting C-peptide levels suggestive of adult-onset T1DM. - Stage III-V renal disease (estimated glomerular filtration rate =30ml/min/1.73m2). - Absolute contraindications to CMR. Importantly, patients with subclinical CAD, and other common comorbidities such as obesity and hypertension, will not be excluded from this study. This will enable us to evaluate the contribution of CAD to myocardial dysfunction in diabetes and ensures our study group is representative of the general population with diabetes. Similarly, as mild dyspnoea is extremely common and non-specific participants with mild dyspnoea will be included.

Study Design


Intervention

Diagnostic Test:
Cardiovascular magnetic resonance (CMR) imaging and magnetic resonance spectroscopy
CMR scanning performed on a 3T MRI scanner. Standardised protocol incorporating cine functional assessment to determine LV mass, systolic function and left atrial volumes; global systolic strain and diastolic strain rates will be assessed by tagging and with tissue tracking analysis from cine images, adenosine rest and stress myocardial perfusion to assess reserve index and qualitative perfusion defects as previously described, aortic distensibility and pulse wave velocity to measure aortic stiffness, delayed contrast enhancement for assessment of LV fibrosis and evidence of previous myocardial infarction. Myocardial and liver triglyceride content will be assessed using the modified Hepafat® sequence or 1H MR spectroscopy at the inter ventricular septum. DIXON technique for the quantification of visceral adiposity and subcutaneous adipose tissue.
Transthoracic echocardiography
Comprehensive transthoracic echocardiography, including: tissue Doppler indices of diastolic filling and speckle tracking for systolic and diastolic strain/strain rate, exclusion of valvular abnormalities, assessment of LV size and function.
Computed tomography coronary artery calcium scoring
Computed Tomography coronary calcium scoring to assess the presence of subclinical atherosclerosis and allow an estimate of atheroma burden in addition to epicardial adipose tissue characterisation and systolic strain.
Cardiopulmonary exercise testing
Physician supervised incremental symptom limited cardiopulmonary exercise tolerance test with ECG and haemodynamic monitoring.
Manganese-enhanced magnetic resonance imaging (MEMRI)
A subset of the participants will have cardiac MRI scanning with manganese-based contrast agent, lasting approximately 45-50 minutes. After localisers, baseline functions and native T1 maps have been acquired, Mangafodipir (0.1mL/kg) will be administered intravenously at 1ml/min, with additional T1 maps acquired every 2.5 min after administration of the contrast agent for up to 30 minutes.
Ambulatory blood pressure monitoring
A 24-hour blood pressure monitor will be worn at the end of the visit to the following day.
Accelerometer watch
Watch worn to collect free living physical activity data for 7 days.
Blood tests
Collection of blood samples from each participant to characterise the participant's health status and to develop a proteomic signature of early heart failure.

Locations

Country Name City State
United Kingdom University of Leicester Leicester

Sponsors (1)

Lead Sponsor Collaborator
University of Leicester

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Prevalence of early heart failure in type 2 diabetes Proportion of participants with type 2 diabetes who have features of early heart failure 5 years
Secondary Multivariate and independent predictors of LV systolic and diastolic function in type 2 diabetes Multivariate and independent predictors of LV systolic and diastolic function in type 2 diabetes 3 years
Secondary Sensitivity of CMR versus echocardiography and BNP for detecting subclinical cardiovascular dysfunction in type 2 diabetes Sensitivity of CMR versus echocardiography and BNP for detecting subclinical cardiovascular dysfunction in type 2 diabetes 3 years
Secondary Independent association of CMR measures with aerobic exercise capacity in type 2 diabetes Independent association of CMR measures (LV systolic and diastolic strain and strain rates) with aerobic exercise capacity (peak VO2) in type 2 diabetes 3 years
Secondary Differences in LV remodelling (indexed LV mass) between cases and controls Differences in LV remodelling (indexed LV mass) between cases and controls 3 years
Secondary Independent clinical and imaging predictors of major adverse cardiovascular and, in particular, heart failure events in the patients with type 2 diabetes Independent clinical and imaging predictors of major adverse cardiovascular and, in particular, heart failure events in the patients with type 2 diabetes 5 years
Secondary Differences in cardiac MRI and echo-derived systolic and diastolic strain and strain rates between cases and controls. Differences in cardiac MRI and echo-derived systolic and diastolic strain and strain rates between cases and controls. 3 years
Secondary Differences in coronary atheroma burden (CT coronary artery calcium score) between cases and controls Differences in coronary atheroma burden (CT coronary artery calcium score) between cases and controls 3 years
Secondary Differences in aerobic exercise capacity (peak V02) between cases and controls Differences in aerobic exercise capacity (peak V02) between cases and controls 3 years
Secondary Differences in myocardial perfusion reserve between cases and controls Differences in myocardial perfusion reserve between cases and controls 3 years
Secondary Differences in heart rate and blood pressure variability between cases and controls Differences in heart rate and blood pressure variability between cases and controls 3 years
Secondary Myocardial steatosis Myocardial steatosis as an independent predictor of LV global longitudinal strain 3 years
Secondary Myocardial calcium handling as assessed by manganese-enhanced magnetic resonance imaging (MEMRI) Manganese influx constants calculated using Patlak modelling 5 years
Secondary Proteomic signature Proteomic analysis will be conducted to identify a proteomic signature of early heart failure in type 2 diabetes that will be externally validated 5 years
Secondary Remission of type 2 diabetes The phenotype of participants defined as in remission will be compared to active type 2 diabetes and healthy volunteers 5 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05666479 - CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
Completed NCT05647083 - The Effect of Massage on Diabetic Parameters N/A
Active, not recruiting NCT05661799 - Persistence of Physical Activity in People With Type 2 Diabetes Over Time. N/A
Completed NCT03686722 - Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin Phase 1
Completed NCT02836704 - Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose) Phase 4
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Completed NCT04562714 - Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy N/A
Completed NCT02009488 - Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT05896319 - Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2 N/A
Recruiting NCT05598203 - Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes N/A
Completed NCT05046873 - A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People Phase 1
Terminated NCT04090242 - Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes N/A
Completed NCT04030091 - Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus Phase 4
Completed NCT03604224 - A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
Completed NCT03620357 - Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D) N/A
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT03620890 - Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy Phase 4
Withdrawn NCT05473286 - A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Completed NCT04531631 - Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes Phase 2